A Phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas

Cancer

Volumn 80, Issue 7, 1997, Pages 1221-1227

  Bokemeyer, Carsten ^a   Franzke, Anke ^b   Hartmann, Jörg T ^a   Schöber, Christoph ^c   Arseniev, Lubomir ^b   Metzner, Bernd ^b   Link, Hartmut ^b   Kanz, Lothar ^a   Schmoll, Hans J ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Adult soft tissue sarcoma; Dose intensity; Doxorubicin; Growth factors; High dose ifosfamide; Nephrotoxicity; Peripheral blood stem cell support; Phase I II studies

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; NEPHROTOXICITY; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; SARCOMA;

EID: 0030885437     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1221::AID-CNCR4>3.0.CO;2-N     Document Type: Article

References (23)

1. Dirix LY, Somville J, Van Oosterom AT. Diagnosis and treatment of soft tissue sarcomas in adults. Curr Opin Oncol 1996;8:289-98.
2. Bokemeyer C, Harstrick A, Schmoll HJ. Treatment of adult soft-tissue sarcomas with intensified chemotherapy and haematopoietic growth factors. Onkologie 1994; 17:216-25.
3. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
4. Bokemeyer C, Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Schöffski P, Poliwoda H. Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. Ann Oncol 1992;3:487-8.
5. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-5.
6. Demetri GD. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bones. Semin Oncol 1996;23:22-6.
7. Tursz T. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Semin Oncol 1996;23:34-9.
8. Cerny T, Leyvraz S, Dazzi H, Varini M, Kroner J, Marti C, et al. Phase II trials of ifosfamide and mesna in advanced soft tissue sarcoma (STS) patients: a definite dose-response relationship [abstract]. Proc Am Soc Clin Oncol 1992;11:1416.
9. LeCesne A, Antoine E, Spielmann M, LeChevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-8.
10. Elias AD, Eder JP, Shea T, Begg CB, Frei III E, Antman KH. High-dose ifosfamide with mesna uroprotection: a Phase I study. J Clin Oncol 1990;8:170-8.
11. Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991;9:320-7.
12. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11:15-21.
13. Palumbo R, Toma S. Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalation doses in advanced soft tissue sarcomas: a Phase I study. Eur J Cancer 1995;31A:1552-3.
14. Bokemeyer C, Kuczyk MA, Könne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 1996;72:1-9.
15. DeVries EG, DeGraaf H, Boonstra A, van der Graaf WT, Mulder NH. High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors. Stem Cells (Dayt) 1995;13:597-606.
16. Leyvraz S, Bacchi M, Cerny T, Lissoni A, Sessa C, Herrmann R. A phase I trial of intensification of ifosfamide and adriamycin and GM-CSF for the treatment of sarcomas [abstract]. Proc Am Soc Clin Oncol 1995;14:515.
17. Buondonna A, Romanini A, Comandone A, Delia Palma M, Verusio C, Frustaci S. Increasing continuous infusion (CI) ifosfamide (IFO) and bolus epirubicin (EPI) in soft tissue sarcoma (STS) patients (PTS) [abstract]. Proc Am Soc Clin Oncol 1996;15:522.
18. Schwartzberg L, Birch R, Blanco R, Wittlin R, Muscato J, Tauer K, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993;11: 369-74.
19. Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994;343:763-4.
20. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-9.
21. Toma S, Palumbo R, Comandone A, Oliva C, Vincenti M, Bumma C, et al. Ambulatory 4-day continuous infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study. Ann Oncol 1995;6:193-6.
22. Comandone A, Frustaci S, Leone L, Santoro A, Oliva C, Bretti S, et al. Ifosfamide in continuous infusion: the pharmacokinetic profile in patients with soft tissue sarcomas [abstract]. Eur J Cancer 1995;31A(Suppl 5):178.
23. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt I, Holmes C, et al. Synovial sarcoma: uniform response of metastases to high-dose ifosfamide. Cancer 1994;73:2506-11.